Evidence map›Paper›PMID 27832536›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2017

eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response.

Ji-Ye Yin, Zizheng Dong, Jian-Ting Zhang

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Ji-Ye YinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, 110 Xiang Ya Road, Changsha, Hunan, 410078, China. yinjiye@csu.edu.cn.
Zizheng DongDepartment of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN, 46202, USA.
Jian-Ting ZhangDepartment of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine, 980 W. Walnut Street, Indianapolis, IN, 46202, USA. jianzhan@iu.edu.
Central South University · CNIndiana University Health · USIndiana University – Purdue University Indianapolis · US

Funding

Therapeutic targeting of stratifin structure and functionR01CA140582 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI ZHANG, JIAN-TING · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA140582
6 · The paper itself

Abstract

Translation initiation is the rate-limiting step of protein synthesis and highly regulated. Eukaryotic initiation factor 3 (eIF3) is the largest and most complex initiation factor consisting of 13 putative subunits. A growing number of studies suggest that eIF3 and its subunits may represent a new group of proto-oncogenes and associates with prognosis. They regulate translation of a subset of mRNAs involved in many cellular processes including proliferation, apoptosis, DNA repair, and cell cycle. Therefore, unveiling the mechanisms of eIF3 action in tumorigenesis may help identify attractive targets for cancer therapy. Here, we describe a series of methods used in the study of eIF3 function in regulating protein synthesis, tumorigenesis, and cellular response to therapeutic treatments.

Indexed as

AnimalsAntineoplastic AgentsApoptosisCarcinogenesisCell SurvivalDrug Screening Assays, AntitumorEukaryotic Initiation Factor-3Gene Expression Regulation, NeoplasticHumansMice, Inbred NODMice, NudeMice, SCIDNeoplasm TransplantationProtein BindingProtein BiosynthesisTumor Cells, CulturedAntineoplastic AgentsEukaryotic Initiation Factor-3Eukaryotic initiation factor 3 (eIF3)Protein synthesisTherapeutic responseTranslational controlTumorigenesis

Identifiers

PMID27832536
PMCPMC8259889
OpenAlexW2551770263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.